LAZ head to its IPO $25. Target $26.5 in the next couple of weeks. TA looks attractive. SCHN target above $30. OS target $20. ADBE target $30. HLTH target $12-$15. RHAT target $16
THis is why LAZ worth at least $26.5 Take a look at this link and you will know why LAZ target is $26.5. However my target is not just based on these analyst opinion, but from FA my model. http://finance.yahoo.com/q/ao?s=LAZ Article from WJS: U.S. deal makers still lead the M&A world July 14th 2005 AFX Asia (c) 2005, AFX Asia. All rights reserved. NEW YORK (XFN-ASIA) - When Chinese oil company CNOOC Ltd. Stunned the markets by making a $18.5 billion bid for Unocal Corp. last month, it didn't lean on China's burgeoning banking industry. Nor did the company go to any Asian-based firm to advise them on the deal. Instead, like many foreign companies, it sought American-made advice from Goldman Sachs Group Inc. , J.P. Morgan Chase and legal advice from Davis Polk & Wardwell. As CNOOC's choice suggests, Chinese mergers and acquisitions may be grabbing headlines, but U.S. investment banks continue to be grabbing the fees for advising on deals. "They have a vast wealth of experience, detailed home country knowledge and are very adroit at hiring people from every country," said James Owers, a Harvard University associate and finance professor at Georgia State University. "When you overlay that with the traditional experience you have competitive advantage." Indeed, though M&A is up in countries around the world, including Japan, the United Kingdom, Italy, Germany, Spain and Russia, the U.S. market remains the hottest with $593 billion in deals through the first half of the year, up 35%, according to Dealogic. China's M&A market is actually having a slower year through the first half, down 15% to $23 billion. That puts the People's Republic 11th globally behind countries like Canada, Australia and the Netherlands. U.S. leaders Through the first half of 2005, four of the top five global advisers were U.S.-based firms: Morgan Stanley , Goldman Sachs, Merrill Lynch & Co. and J. P. Morgan ranked one through four. Swiss bank UBS placed fifth. Owers cautions that U.S. banks and sellers such as Unocal may learn a lesson from the late 1980s and early 1990s. At that time, foreign buyers, including many from Japan, bought U.S. assets. The fear about foreign ownership incited nationalism and protectionism, Owers said. But, in the end, the sellers and bankers were the ones who profited. "If someone offers you more than market price, give them the keys and let them drive it away," Owers said. Shrinking competition It was only a few years ago when firms such as Lazard Ltd., Cazenove, and Schroeders were considered top competitors emerging from Europe. But Lazard booted its European management for U.S. banker Bruce Wasserstein and went public on the New York Stock Exchange. J.P. Morgan bought a 50% stake in Cazenove in 2004 and Schroeders was acquired by Citigroup for $2.2 billion in 2000. In their place, banks such as HSBC Holdings under John Studzinski, Deutsche Bank , Dresdner Kleinwort Wasserstein and Nomura remain second-tier players with bigger ambitions. Even in Europe U.S. banks remain the heavyweights in Europe taking advising roles in the two biggest deals of the year. When Bayerische Hypo Vereinsbank agreed to be acquired by UniCredito Italiano in June for $18.6 billion, J.P. Morgan, Citigroup, and Deutsche Bank advised the target. Merrill Lynch and Goldman advised the buyer. Likewise when Pernod Richard and Fortune Brands agreed to buy Allied Domecq in April for $17.7 billion, Goldman advised Allied, three U.S. banks advised the buyer with Deutsche Bank, CSFB and BNP Paribas. That U.S. firms are leading the deals isn't new and isn't likely to change. "They are aggressive in their strategy," Owers said. "If you're good at something and have a good strategy...you will be dominant." This story was supplied by MarketWatch. For further information see www. marketwatch.com. MMMM
Regeneron Pharmaceuticals Attend July 22th Obesity Drug Development Summit http://www.cbinet.com/show_conference.cfm?confCode=HB549&field=daytwo In Vivo Target Discovery and Validation by High Throughput Genome Engineering A high throughput genome engineering technology platform has been developed to determined the in vivoexpression pattern of many novel obesity and diabetes-related genes at high resolution, validate and invalidate putative targets as well as dissected important metabolic pathways. This method also provides important insights into mechanisms of novel compounds currently in development for the treatment of obesity and diabetes. Overview of technology Validation and invalidation of diabesity targets using KO models SHIP2 lipid phosphatase as target for treatment of obesity Mark W. Sleeman, Ph.D., Director of Neural and Endocrine Biology,Regeneron Pharmaceuticals Inc. Watch REGN these days, getting hotter and hotter. Valueline raise its timeliness on June based on REGN's much-better-than-before financial statement and its new drugs research with its target $15. Three years target from Valueline is $25.
FLEX strong buy. Target $20 end of 2005. Will see appreciation recently with its earning soon this month. Market Concensus 0.16, but valueline gave out their estimate 0.18 due to the Nortel contract. Flextronics earned $0.16 a share in the fiscal fourth quarter (ended March 31st). The top line was likely about $4.0 billion in the period. Revenues probably benefited from roughly $100 million in initial contributions from its major deal with Nortel Networks, and a moderate recovery in the telecom, computer, and consumer markets. The core electronics manufacturing-services (EMS) business should grow at a decent pace. We look for low single- digit percentage advancements in key end markets, including cellphones and information technology. Plus, revenues from the industrial, medical, and auto industries ought to climb rapidly this year. Many additional opportunities exist in those end markets, which should comprise an increasing portion of FLEX's top line. We think FLEX will gain much new outsourcing business during fiscal 2005, thanks in part to companies looking to mitigate the impact of high energy costs. The Nortel contract will ramp up significantly this year. Revenues from that telecom equipment manufacturer should be roughly $300 million in the June quarter, and $500 million in the September period. The agreement will likely be solidly accretive to share earnings in fiscal 2005. Acquisition costs during calendar 2005 will run about $700 million. As the contract expands to include printed circuit boards (PCBs) and enclosures, annual revenues ought to be between $2 billion and $2.1 billion. Operating margins should continue to widen this fiscal year and next. Operating cost containment and improved capacity utilization should assist margins. Plus, a greater proportion of higher-margined products and services, such as network services and PCBs, ought to drive gross margin expansion. However, Nortel's higher-cost facilities will likely hamper margins to some degree. Flextronics shares are a good long-term holding for risk-tolerant investors. More end-to-end supply chain service offerings, such as with Nortel, should support earnings growth out to 2008-2010. In particular, the high-margined original-design-manufacturing business is poised to deliver $4 billion annually to the top line.
FLEX strong buy. Target $20 end of 2005. Will see appreciation recently with its earning soon this month. Market Concensus 0.16, but valueline gave out their estimate 0.18 due to the Nortel contract. Flextronics earned $0.16 a share in the fiscal fourth quarter (ended March 31st). The top line was likely about $4.0 billion in the period. Revenues probably benefited from roughly $100 million in initial contributions from its major deal with Nortel Networks, and a moderate recovery in the telecom, computer, and consumer markets. The core electronics manufacturing-services (EMS) business should grow at a decent pace. We look for low single- digit percentage advancements in key end markets, including cellphones and information technology. Plus, revenues from the industrial, medical, and auto industries ought to climb rapidly this year. Many additional opportunities exist in those end markets, which should comprise an increasing portion of FLEX's top line. We think FLEX will gain much new outsourcing business during fiscal 2005, thanks in part to companies looking to mitigate the impact of high energy costs. The Nortel contract will ramp up significantly this year. Revenues from that telecom equipment manufacturer should be roughly $300 million in the June quarter, and $500 million in the September period. The agreement will likely be solidly accretive to share earnings in fiscal 2005. Acquisition costs during calendar 2005 will run about $700 million. As the contract expands to include printed circuit boards (PCBs) and enclosures, annual revenues ought to be between $2 billion and $2.1 billion. Operating margins should continue to widen this fiscal year and next. Operating cost containment and improved capacity utilization should assist margins. Plus, a greater proportion of higher-margined products and services, such as network services and PCBs, ought to drive gross margin expansion. However, Nortel's higher-cost facilities will likely hamper margins to some degree. Flextronics shares are a good long-term holding for risk-tolerant investors. More end-to-end supply chain service offerings, such as with Nortel, should support earnings growth out to 2008-2010. In particular, the high-margined original-design-manufacturing business is poised to deliver $4 billion annually to the top line.
Versatel Finally Bought, Tele2 Pays EUR1.3B By Arent Jan Hesselink " Morgan Stanley & Co (MDW) Limited acts as financial advisor to Tele2, ABN Amro Holding NV (ABN) was advisor to Apax and Versatel was advised by Lazard (LAZ). " Lazard's Euro M&A business.
ACN report http://biz.yahoo.com/fool/050719/112179072914.html?.v=1 Pay attention to PAYX, RECN, RHI recent jump on the global outsourcing business expansion. ACN is one of the largest outsourcing services firms in US, this stock will follow the sector trend. My target is $30 for this one.
NGPS almost $34, REGN $9.8, I call REGN $8.9 two weeks ago. Now FLEX July 26 earning, the valueline estimate beat the market consensus, I bet FLEX's earning will beat the expectation. Target $20